Printer Friendly

Implementing intensified treatment strategies for patients with type 2 diabetes mellitus.

Primary care physicians play central roles in the management of patients with diabetes, providing care for approximately 90% to 95% of adult patients with type 2 diabetes mellitus (DM). (1) Treatment goals are well established, although treatment guidelines continue to evolve in response to new evidence and advances in therapy. Clinicians face significant challenges in managing this multi-faceted and complex disease. Less than 12% of diagnosed patients reach treatment goals for blood glucose, cholesterol, and blood pressure (BP). (2)

Treatment typically begins with the use of single-agent pharmacotherapy in conjunction with lifestyle modifications. As the disease progresses, other pharmacologic agents are added as treatment is intensified to achieve target goals. This CME activity examines the clinical uncertainties resulting from disease progression and provides recommendations for the long-term management of patients with type 2 DM.
   PATIENT CASE Eric, age 45 years, presents
   to his family physician, Dr Moore, for his first routine
   examination in 7 years. Eric would not have
   scheduled this visit had his wife not insisted that
   he discuss his 8-1b weight gain over the past year
   and seek prompt initiation of an exercise regimen.
   Eric notes that he wakes nightly to urinate and
   asks if this is normal. Family history is notable for
   a brother with type 2 DM.

   Physical examination reveals Eric is 5
   feet, 9 inches tall and weighs 180 lb, with
   a body mass index (BMI) of 26.6 kg/[m.sup.2].
   His blood pressure (BP) is 138/88 mm Hg.
   Other than the somewhat overweight body
   habitus, ophthalmologic, neck, cardiovascular,
   abdominal, extremity/skin, and neurologic
   examination results are normal.

   Because of Eric's age, reported
   inactivity, and slightly elevated BMI and
   BP, laboratory work is ordered. Results
   show several abnormalities: fasting glucose
   (FG) of 165 mg/dL; high-density
   lipoprotein cholesterol (HDL-C), 45 mg/
   dL; low-density lipoprotein cholesterol
   (LDL-C), 110 mg/dL; total cholesterol
   (TC), 189 mg/dL; triglycerides (TG), 170
   mg/dL; creatinine, 0.9 mg/dL; urinalysis,
   no albumin and trace glucose; and electrocardiogram,
   normal. Repeat FG is 162
   mg/dL. Dr Moore orders a glycosylated
   hemoglobin test (A1C), which shows a
   level of 7.8%.


Issues for clinicians

Eric's infrequent medical care history-not uncommon for men in his age group-presents an additional treatment issue. Aggressive blood glucose regulation is essential to prevent diabetes complication; normalization of blood glucose is the cornerstone of disease management. The goal for every patient is to normalize AIC levels to less than 7% within 3 months while avoiding hypoglycemia, particularly severe hypoglycemia. (3)

Type 2 DM is a well-recognized consequence of insulin resistance and its resultant syndrome, with other components that include hypertension, hyperlipidemia, and obesity. Clearly, it is of vital importance to address a patient's weight, BP, LDL-C, HDL-C, and triglycerides.

Importance of glycemic control

Issues of glycemic control dictate future treatment and outcomes for every patient with diabetes.

An FG level greater than 140 mg/dL (7.8 retool/L) increases the risk for complications such as diabetic retinopathy. (4) Strict glycemic control reduces risk for microvascular (retinopathy, nephropathy, and neuropathy) and macrovascular (myocardial infarction [MI] and stroke) complications. (5,6)

Current American Diabetes Association (ADA) recommendations (TABLE 1) for glycemic control feature an AIC goal of less than 7% for patients in general and an A1C as close to normal (less than 6%) for the individual patient. (7) In the United Kingdom Prospective Diabetes Study (UKPDS), each 1% reduction in AIC level was associated with a decreased risk of 37% for microvascular disease, 14 % for MI, 21% for diabetes-related deaths, and 14% for all-cause mortality. (6) The current and growing impact of type 2 DM in the United States is summarized in TABLE 2.

Glycemic control: A long-term challenge

Lifestyle modification remains the mainstay of diabetes treatment and prevention, although diet and exercise alone often do not succeed long-term. The UKPDS showed that, despite an intensive 3-month dietary program, excellent glycemic control (FG, [less than or equal to] 108 mg/dL) was achieved by only 16% of participants. (8)

Additional interventions will likely be required over time; normoglycemia may be achievable only with early use of pharmacologic agents. The ADA recommends initiating treatment with lifestyle management and metformin. (7) The American Association of Clinical Endocrinologists (AACE) recommends lifestyle management and combination pharmacologic treatment when a patient has an AIC level of 7% to 8%. (3)

Even at an early stage, the progressive nature of the disease means that each treatment's efficacy will diminish over time. Given the potentially devastating effects of hyperglycemia, physicians must favor proactive diabetes management and appropriate intensification of treatment to delay or prevent complications. Approximately 50% of patients using antihyperglycemic medication need to advance from monotherapy to combination therapy by year 3 of treatment. (9) Currently available treatment options appear in ADDENDUM 1 AND ADDENDUM 2.
   PATIENT CASE

   Dr Moore diagnoses new-onset type 2
   DM. The diagnosis surprises and upsets
   Eric. Dr Moore is sympathetic, noting
   that the signs and symptoms of type 2
   DM progress slowly; most people are unaware
   they have the disease. He advises
   Eric that both type 2 DM and cardiovascular
   problems can be managed effectively,
   provided Eric adheres to the treatment
   plan that they develop together.

   Dr Moore outlines the issues that
   must be addressed; however, given
   Eric's state of mind, he focuses on management
   of hyperglycemia. He tells Eric
   that other health issues need to be discussed
   at his next visit. Eric agrees.

   They decide on a strict diet and
   exercise plan. Although the 2007 AACE
   guidelines recommend combination pharmacologic
   therapy when a patient has
   an A1C level between 7% and 8%, (3) Dr
   Moore recommends initiation of metformin
   monotherapy, as recommended by
   the ADA. (7)

   Eric exhibits no evidence of microvascular
   damage. Dr Moore does not
   discuss these aspects of the disease
   because he does not want to overwhelm
   Eric, potentially risking Eric's adherence
   to follow-up. A dose of metformin, 500
   mg BID after meals, is chosen. They also
   discuss proper initiation of self-monitoring
   blood glucose (SMBG). Eric receives
   influenza and pneumonia immunizations
   and schedules meetings with a diabetes
   educator. Dr Moore establishes a timeline
   in which to reduce Eric's A1C level to
   under 7% within 3 months.


Initiating and intensifying therapy

Dr Moore recognized that applying guidelines to the management of a specific patient often requires careful consideration and flexibility. Rather than initiate multiple therapies to treat the various problems Eric is experiencing, Dr Moore determined that initially focusing on one problem (hyperglycemia), while reaching agreement with Eric about the need for more comprehensive long-term management, was a better approach for Eric. Dr Moore initiated lifestyle management and metformin monotherapy, as recommended by the ADA. This plan is somewhat more aggressive than lifestyle management alone, which has typically been done in the past. For most patients, progressive initiation of therapy, guided by SMBG, will be needed to maintain glycemic control.
   PATIENT CASE

   Eric presents 3 months after initiating
   metformin and lifestyle management.
   He has met with the diabetes educator
   several times and feels less anxious
   about his diagnosis. His FG level is 138
   mg/dL, and his A1C level is 7.6%. His
   glucose diary shows postprandial levels
   of 140 to 160 mg/dL. Eric has lost 6 lb.
   His metformin dose is increased to 850
   mg TID after meals. Dr Moore and Eric
   review cardiovascular issues; they agree
   to start aspirin and an angiotensin-converting
   enzyme (ACE) inhibitor; a statin
   will be added at the next visit.

   At a follow-up visit 3 months later,
   Eric's A1C level is 7.5%. Dr Moore adds
   glyburide 10 mg BID. This agent is selected
   because of cost. The statin is added.


Additional agent to meet glycemic goal

If a patient is unable to meet glycemic goals with metformin monotherapy, adding a second oral agent should be considered. Patients also must be aware of the progressive nature of diabetes. Future needs will likely include insulin, which can be described as a "natural" treatment to replace the deficit inherent in patients with diabetes. Both patients and physicians need to understand that insulin can effectively produce good glycemic control. If insulin use is avoided, suboptimal glycemic control and long-term complications may result.
   PATIENT CASE

   Three months later, Eric's A1C level is
   6.9%. He has lost an additional 4 lb. His
   BP has decreased to 134/84 mm Hg,
   and his lipid profile has improved: HDL-C
   is 50 mg/dL; LDL-C, 102 mg/dL; TC, 178
   mg/dL; and TG, 160 mg/dL. No change
   is made to his metformin/glyburide regimen.
   Dr Moore increases the dosage of
   Eric's ACE inhibitor and statin. Over the
   next year, Eric's BP and lipid profile improve
   to a level within the target range for
   a patient with type 2 DM.

   One year later, Eric's A1C level has
   risen to 8.2%, despite a stable weight
   and claims of an unchanged diet. Eric
   does note that his work and home life
   have prevented him from exercising for 6
   months. Eric's A1C level correlates with
   his FG level of 152 mg/dL. Postprandial
   glucose levels have ranged from 165
   to 195 mg/dL. Dr Moore considers administration
   of exenatide but rules out
   this agent, which typically reduces A1C
   levels by less than 1%. Eric requires a
   reduction of at least 1.2%; therefore, a
   long-acting insulin analog is needed.

   Because Eric's weight has been an
   issue, Dr Moore chooses insulin detemir,
   10 units once a day. Eric will administer
   the detemir at bedtime; Dr Moore instructs
   Eric to increase the dose slowly.

   Dr Moore encourages Eric to continue
   to work with the diabetes educator
   to address his concerns regarding the
   initiation of insulin, particularly any concerns
   he may have about needles and
   hypoglycemia. (10)

   After 3 months' use, the detemir dose
   has been titrated to 36 units once a day.
   Eric's A1C level is 7.2%. At 6 months,
   the detemir dose of 46 units once a day
   yields an A1C level of 6.6%.


Maintaining glycemic control

Well-established basal-bolus insulin regimens combine long-acting basal insulin and short-acting prandial insulin before meals. The older combination, featuring short-acting regular insulin and longer-acting neutral protamine Hagedorn (NPH) insulin, was not optimal for 2 reasons: regular insulin does not work fast enough, and NPH insulin lacks an appropriately prolonged duration of action. (11) Insulin analogs address these shortcomings; faster action provides more immediate postprandial control and longer action creates less serum peaks and hypoglycemia. Physiologic insulin patterns are initiated by basal-bolus regimens incorporating the insulin analogs, thus potentially offering important benefits in controlling hyperglycemia.
   PATIENT CASE

   While using insulin detemir, Eric's A1C
   level is stable. His cardiac profile remains
   within acceptable levels (no change to
   his ACE inhibitor and statin). At his most
   recent office visit, Eric's A1C level has
   increased to 7.8%; FG is normal, at
   110-120 mg/dL. Dr Moore is concerned
   that postprandial hyperglycemia is causing
   the elevated AIC level; he asks Eric
   to record 2-hour postprandial glucose
   levels for 2 weeks. Levels range from
   190 to 220 mg/dL and are especially
   high following dinner. Recent studies
   suggest the significant contribution of
   postprandial glucose levels to A1C. (12)
   Dr Moore adds a rapid-acting analog,
   to be taken prior to dinner, in addition
   to nightly basal insulin. He encourages
   Eric to continue checking postprandial
   glucose levels. Eventually, the administration
   of the rapid-acting analog is increased
   to 3 times a day prior to meals,
   because of higher postprandial sugars
   after breakfast and dinner, coupled with
   an A1C level of 7.4%. Eric's glycemic
   control is significantly improved, and his
   A1C level falls to 6.7% within 6 months.


Conclusion

Diabetes is as multifaceted as the treatment options available to manage it. Glycemic control represents the critical factor in diabetes management and provides the greatest opportunity for preventing complications of diabetes in newly diagnosed patients. As this case shows, the progressive nature of type 2 DM makes long-term glycemic control a challenge. Timely modification and intensification of therapy, guided by ongoing monitoring of glycemic endpoints, is of utmost importance. The central role of the patient in the self-management of type 2 DM mandates ongoing patient education. As patient and clinician effectively utilize available treatment options and work together as a team, they can reduce the morbidity and mortality of diabetes and its associated comorbidities.

References

(1.) Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:361-376.

(2.) US Department of Health and Human Services, National Institutes of Health. Most people with diabetes do not meet treatment goals. NIH News. January 20, 2004. http://www.nih.gov/news/pr/ jan2004/niddk-20.htm. Accessed June 22, 2007.

(3.) AACE Diabetes Mellitus Clinical Practice Guideline Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(suppl 1):1-68.

(4.) United Kingdom Prospective Diabetes Study Group. United Kingdom prospective diabetes study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphenylurea, insulin, or metformin in patients with newly diagnosed noninsulin dependent diabetes followed for three years. BMJ. 1995;310:83-88.

(5.) Reichard P, Nilsson B-Y, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:304-309.

(6.) Stratton IM, Adler AI, Nell HAW, et al, on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.

(7.) American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care. 2007;30(suppl 1):$4-$41.

(8.) United Kingdom Prospective Diabetes Study Group, United Kingdom prospective diabetes study (UKPDS) 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group. Metabolism. 1990;39:905-912.

(9.) Turner RC, Cull CA, Frighi V, et al, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. JAMA. 1999;281:2005-2012

(10.) White RD. Options for insulin delivery and overcoming physician and patient concerns. J Fam Pract. 2006:55(12 suppl):l 8-24.

(11.) Gummerson I. Insulin analogues. Revisited. Hospital Pharmacist. 2003;10:165-173.

(12.) Monnier L, Lapinkski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1 c). Diabetes Care 2003; 26:881-885.

Stephen A. Brunton, MD, FAAFP

Director of Faculty Development

Cabarrus Family Medicine Residency

Concord, North Carolina

Arturo R. Rolla, MD

Associate Professor of Clinical Medicine, Harvard Medical School

Senior Endocrinologist, Beth Israel Deaconess Medical Center

Boston, Massachusetts
TABLE 1

Summary of ADA Recommendations
for Glycemic Control

A1C                                             <7% *

Preprandial capillary                      90 to 130 mg/dL
plasma glucose

Peak postprandial capillary                <180 mg/dL
plasma glucose

A1C, glycosylated hemoglobin.

* As close to 6% as possible is preferred as long as hypoglycemia is
avoided.

TABLE 2
The Impact of Type 2 Diabetes

* Affects 10% of the US adult population

* Accounts for >27 million office visits and >72,000
  deaths annually

* Represents the sixth leading cause of death in
  the United States

* Presents a projected lifetime risk for disease
  development of 33% to 38% for Americans born
  in 2000

* Continues to increase in impact, despite advances in
  treatment. The National Health and Nutrition Examination
  Surveys showed that the average A1C level in
  patients with type 2 DM rose from 7.8% between 1988
  and 1994 to 8.1% between 1999 and 2000

DM, diabetes mellites.

Source: Ziemer DC, et al. Arch Intern Med. 2006;166:507-513.
Centers for Disease Control and Prevention.
www.cdc.g0v/nchs/fastats/diabetes.htm
Accessed June 22, 2007.


Addendum 1 Available Agents for Glycemic Control

Oral antihyperglycemic agents

* SULFONYLUREAS can reduce fasting glucose levels by 50 to 70 mg/dL, but they have little influence on post-prandial levels. Also known as beta cell stimulants, they are most effective in patients whose beta cells still create a considerable amount of insulin. Glimepiride and glipizide can reduce glycosylated hemoglobin (A1C) levels by 1% to 2%. The glinides, repaglinide, and nateglinide are administered close to a meal, thus increasing effectiveness in reducing postprandial glucose levels. They have less effect on fasting blood glucose levels?

* ALPHA-GLUCOSIDASE INHIBITORS, acarbose and miglitol, can reduce postprandial glucose levels by 30 to 50 mg/dL, fasting glucose levels by 15 to 20 mg/dL, and A1C levels by 0.5% to 0.8%. They delay glucose absorption in the gut and must be taken at the beginning of a meal. They are best used as monotherapy in patients for whom postprandial hyperglycemia is the main concern. These agents are associated with gastrointestinal (GI) side effects (eg, flatulence, abdominal cramping, and diarrhea). (1)

* METFORMIN can lower fasting glucose levels by 50 to 70 mg/dL and A1C levels by 1% to 2%. It reduces insulin levels and hepatic glucose production, with the added benefit of reducing plasma triglycerides and low-density lipoprotein cholesterol levels, and possibly increasing high-density lipoprotein cholesterol levels? Lactic acidosis is a rare adverse event (AE) associated with the use of metformin. Dependent on renal clearance, it should not be used in patients with or at risk for renal insufficiency. (1)

* THIAZOLIDINEDIONES (TZDs), pioglitazone and rosiglitazone, can reduce fasting glucose levels by 40 to 60 mg/dL and A1C levels by .5% to 1.4%. A recent meta-analysis of 42 clinical trials noted that rosiglitazone was associated with risk of myocardial infarction (MI) (significant risk) and with death from cardiovascular causes (borderline significance). (3) Similar findings were observed in a recent meta-analysis of studies in which rosiglitazone was used for a minimum of 12 months. (4) A meta-analysis of pioglitazone reported a significantly lower risk of death, MI, and stroke. The incidence of serious heart failure was increased but was not associated with an increase in mortality. (5)

In August 2007, the US Food and Drug Administration (FDA) updated its precautions and contraindications on the use of TZDs. Trials on both agents suggest an increased risk of AEs including worsening edema and increased dyspnea, and heightened use of heart failure medications. Because of these post-marketing reports, new boxed warnings have been added to both agents' prescribing information. The FDA requests that clinicians incorporate this recent information when determining whether to prescribe these agents. (6)

Insulin treatment options

* HUMAN INSULIN is injected subcutaneously at least 30 minutes prior to meals. It peaks at 2 to 4 hours. Considered a short-acting insulin, duration of action is 8 to 10 hours and is, therefore, unsuitable for postprandial glucose management.

* NEUTRAL PROTAMINE HAGEDORN (NPH) insulin, created by adding a protamine molecule to regular insulin, (7) offers slow absorption and a duration of action of 10 to 20 hours, peaking at 4 to 8 hours. This increases the risk of hypoglycemia, especially when administered at bedtime.

* INSULIN ANALOGS are synthetic alternatives that feature a modified insulin molecule structure that more closely mimics physiologic insulin secretion. Both long-acting (basal) and rapid-acting (prandial or bolus) insulin analogs are available. Available long-acting analogs are insulin glargine and insulin detemir. Both have an onset of action of 1 to 2 hours, a steady activity plateau, and a relatively flat peak over 24 hours. Consequently, both are often administered once daily. (8)

Compared with NPH insulin, insulin detemir has a more predictable dosing profile. It produces less within-subject variability in fasting glucose levels, a lower incidence of hypoglycemic events, and a reduced incidence of weight gain than do NPH insulin or insulin glargine. (9)

* RAPID-ACTING ANALOGS--insulin aspart, insulin lispro, and insulin glulisine--are injected within 15 minutes of a meal. They can be used alone or as part of a basal-bolus regimen. (10)

Insulin aspart is approved for use in adults with type 1 or type 2 DM by subcutaneous injection or an external infusion pump. (11) Compared with regular insulin, insulin aspart demonstrates improved plasma glucose excursion determined by postprandial glucose levels. (12) One study demonstrated a 20% reduction in postprandial glucose with insulin aspart versus regular insulin. (10) Insulin aspart has been shown to improve A1C levels and quality-of-life measures versus regular insulin, with similar incidence of hypoglycemic events. (12)

Insulin lispro has been shown to produce a postprandial glucose level 53% lower than that seen with regular insulin. (10) Hypoglycemic episodes are also reduced with this agent. (12)

Insulin glulisine is approved for use in adults with type 1 or type 2 DM by subcutaneous injection or an external infusion pump. (13)

* PREMIXED INSULIN. Many patients maintain glycemic control with the combined use of a rapid- or short-acting insulin and a long-acting insulin. For example, in patients with type 1 or type 2 DM, insulin aspart premix 70/30 significantly reduced postprandial hyperglycemia without increasing the risk of hypoglycemia compared with human insulin premix 70/30. (14)

* INHALED INSULIN. A fine, dry, powdered form of regular insulin is now available for use as an oral inhalant administered before meals. It exhibits an early, quick rise and a duration of action shorter than regular insulin, offering a more physiologic profile during meals. Data suggest that inhaled insulin is well tolerated; however, it is contraindicated in smokers (active or within the previous 6 months) and in patients with asthma or lung disease, (15) Pulmonary function should be assessed prior to initiation and periodically thereafter. (16)

References

(1.) Riddle MC, Genuth S. Type 2 diabetes: treatment. ACP Medicine Online. http://www.medscape.com/ viewarticle/548773?rss. Accessed October 9, 2007.

(2.) Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Eng/ J Med. 2007;356: 2457-2471.

(3.) Singh S. Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298:1180-1195.

(4.) Lincoff AM, Wolski K, Nicholls S J, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180-1188.

(5.) US Food and Drug Administration. Information for Healthcare Professionals: Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl). http://www.fda.gov/cder/drug/InfoSheets/HCP/ rosiglitazone200707HCP.htm. Accessed August 17, 2007.

(6.) US Food and Drug Administration. Information for Healthcare Professionals: Pioglitazone HCI (marketed as Actos, Actoplus Met, and Duet-act). http://www.fda.gov/cder/drug/infopage/ pioglitazone/default.htm. Accessed August 31, 2007.

(7.) DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA. 2003;289:2254-2264.

(8.) Gummerson I. Insulin analogues. Revisited. Hospital Pharmacist. 2003;10:165-173.

(9.) Jones MC, Patel M Insulin detemir: a long-acting insulin product. Am J Health-Syst Pharm. 2006;63:2466-2472.

(10.) Leal S, Herrier RN, Soto M. The role of rapid-acting insulin analogues and inhaled insulin in type 2 diabetes mellitus. Insulin. 2007;2:61-67.

(11.) US Food and Drug Administration. Novolog Package Insert. http://www.fda.gov/medwatch/ SAFETY/2005/Oct_PVNovoLog_PI.pdf. Accessed August 1,2007.

(12.) Fedutes BA, Donihi AC, Culley CM, et al. An evidence-based summary of insulin analogues. P&T 2005;30:112-123.

(13.) Insulin glulisine. Micromedex Update. 2004. http://miromedex.com/products/updates/drugex_updates/de/insulin.html. Accessed October 6, 2007.

(14.) Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med. 2002;19:393-399. Erratum in: Diabet Med. 2002;19:797.

(15.) Rave K, Bott S, Heinemann L, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care. 2005;28:1077-1082.

(16.) Exubera [prescribing information]. January 2007. New York, NY. Pfizer Labs. http://www.pfizer.com/ pfizer/download/uspi_exubera.pdf. Accessed August 17, 2007.
TABLE 1 A
Treatment Options: Monotherapy

Intervention                                  Expected decrease
                                                 in A1C (%)

Lifestyle to decrease
weight/increase activity                           1.0-2.0
Sulfonylureas                                        1.5
Alpha-glucosidase inhibitors                       0.5-0.8
Metformin                                            1.5
Thiazolidines                                      0.5-1.4
Insulin                                            1.5-2.5
Exenatide                                          0.5-1.0
Glinides                                           1.0-1.5
Pramlintide                                        0.5-1.0

A1C. glycosylated hemoglobin.

TABLE - 2A

Treatment Options: Combination

Intervention                                   Expected decrease
                                                  in A1C (%)

Sulfonylurea + metformin                              1.7
Sulfonylurea + rosiglitazone                          1.4
Sulfonylurea + pioglitazone                           1.2
Sulfonylurea + acarbose                               1.3
Repaglinide + metformin                               0.1
Pioglitazone + metformin                              0.7
Rosiglitazone + metformin                             0.8
Dipeptidyl-peptidase                                  0.7
4 inhibitor + metformin
Dipeptidyl-peptidase                                  0.7
4 inhibitor + pioglitazone

A1C, glycosylated hemoglobin.

Reprinted with permission: AACE Diabetes Mellitus Clinical Practice
Guideline Task Force. American Association of Clinical
Endocrinologists medical guidelines for clinical practice
for the management of diabetes mellitus. Endocr Pract.
2007,13(supp 1):1-68.


Addendum 2 Newer Agents for Glycemic Control

The injectable antihyperglycemic agents, pramlintide and exenatide, are gastrointestinal (GI) hormone drugs. These agents can produce a reduction in A1C levels of up to 1%. Pramlintide, a synthetic form, or analog, of the hormone amylin, can be prescribed for patients who have not achieved optimal glycemic control with basal and preprandial insulin. It slows gastric emptying and suppresses glucagon levels, resulting in better postprandial control, reducing A1C levels by approximately 0.5%, and, frequently, reducing food intake and body weight. Exenatide, a peptide derived from Gila monster saliva, is an agonist of glucagon-like peptide 1 (GLP-1) receptors, and can be used in combination with a sulfonylurea, metformin, or both. It is associated with an increase in insulin secretion.

New glucoregulatory agents--amylin agonists, GLP-1 receptor agonists, and dipeptidyl peptidase (DPP)-IV inhibitors--complement currently available agents. In nondiabetic individuals, glucoregulatory hormones such as insulin, amylin, glucagon, and GLP-1 interact to achieve normal glucose homeostasis; however, in patients with diabetes, these hormones are abnormally regulated. (2)

Amylin is a natural glucoregulatory hormone found within pancreatic beta cells along with insulin. It is secreted with insulin as a postprandial response to a glucose load, and it complements the effects of insulin. Patients with type 1 DM have an absolute deficiency of amylin; a relative deficiency of amylin is present in patients with type 2 DM. To increase levels of amylin, the amylin agonist pramlintide can be injected subcutaneously before major meals, resulting in reduced postprandial glucose excursions possibly related to the prevention of a postprandial glucagon rise. The movement of nutrients between the stomach and small intestine is also slowed with pramlintide, prolonging gastric-emptying time by approximately 90 minutes. The addition of pramlintide to insulin therapy has been shown to produce a 0.5% to 1% reduction in A1C levels as well as a reduction in body weight. An average loss of 2.4 kg has been demonstrated in patients with type 2 DM with a BMI greater than 35 kg/[m.sup.2] after treatment with pramlintide for 26 weeks. (2)

GLP-1, an incretin hormone, stimulates insulin secretion, controls glucagon secretion, and delays gastric emptying. It has been shown to reduce appetite and produce weight loss. Patients with type 2 DM secrete lower levels of GLP-1 during meals than do nondiabetic individuals. When administered via continuous intravenous infusion, native GLP-1 produces an instant decrease in blood glucose levels in patients for whom sulfonylurea therapy has failed, resulting in significant effects on fasting and 8-hour plasma glucose, A1C levels, and weight loss. However, native GLP-1 is quickly metabolized by DPP-IV. In addition, GLP-1 must be present continuously in the blood stream to be effective. (3) The long-acting GLP-1 analog liraglutide is now being studied and acts as a full agonist to the GLP-1 receptors. Its half-life after single and multiple dosing is approximately 12 hours in both healthy individuals and patients with type 2 DM. It can be administered once daily by injection. DPP-IV inhibitors slow degradation of GLP-1 to boost availability. These drugs decrease blood glucose levels in patients with type 2 DM, when used either independently or in combination with other antihyperglycemic medications. Both of the available DPP-IV inhibitors are associated either with decreased or unchanged body weight. (4) Thus, by potentiating the natural incretins, the DPP-IV inhibitors provide yet another avenue toward glucose control.

References

(1.) Riddle MC, Genuth S. Type 2 diabetes: treatment. ACP Medicine Online. http://www.medscape.com/viewarticle/548773?rss. Accessed October 9, 2007.

(2.) Ruse JR, Weyer C, Maggs DG. Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clin Diabetes. 2002;20:137-144.

(3.) Madsbad S, Schmitz O, Ranstam J, et al, on behalf of the NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide. Diabetes Care. 2004;27:13351342.

(4.) Hinnen D, Neilsen LL, Waninger A, Kushner P. Incretin mimetics and DPP-IV inhibitors: New paradigms for the treatment of type 2 diabetes. J Am Board Fam Med. 2006;19:612-620.
COPYRIGHT 2007 Quadrant Healthcom, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Author:Brunton, Stephen A.; Rolla, Arturo R.
Publication:Journal of Family Practice
Article Type:Report
Geographic Code:1USA
Date:Nov 1, 2007
Words:4787
Previous Article:Recognizing bipolar disorder on initial presentation: a case study with decision points.
Next Article:PURLS--translating research into reality.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters